EBITDA Margin % is calculated as EBITDA divided by its Revenue. Fuse Medical's EBITDA for the
three
months ended in Jun. 2023 was $0.40 Mil. Fuse Medical's Revenue for the
three
months ended in Jun. 2023 was $5.00 Mil. Therefore, Fuse Medical's EBITDA margin for the quarter that ended in Jun. 2023 was 8.04%.
Fuse Medical (OTCPK:FZMD) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fuse Medical EBITDA Margin % Related Terms
Fuse Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Fuse Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FZMD vs GTHP, SONX, PBIO: EBITDA Margin % Comparison
For the Medical Devices subindustry, Fuse Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fuse Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fuse Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fuse Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuse Medical (FZMD) has a EBITDA Margin % of 8.04% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fuse Medical and its competitors.
Is Fuse Medical's EBITDA Margin % too high?
Fuse Medical's current EBITDA Margin % is 8.04%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Fuse Medical's value of 8.04% is 7.6% above this industry median. Overall, Fuse Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Fuse Medical's EBITDA Margin % compare to GTHP and SONX?
Fuse Medical's EBITDA Margin % of 8.04% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.48. Fuse Medical's value of 8.04% is 7.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fuse Medical's current EBITDA Margin % of 8.04% is 7.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fuse Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuse Medical's current EBITDA Margin % is 8.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuse Medical stock overvalued right now?
Fuse Medical (FZMD) has a current EBITDA Margin % of 8.04%. The current EBITDA Margin % is 8.04% and 7.6% above the Medical Devices & Instruments industry median of 7.48. Fuse Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fuse Medical (FZMD), the current EBITDA Margin % is 8.04% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fuse Medical Inc is a manufacturer, distributor, and wholesaler of medical device implants, offering portfolio of orthopedic implants and biologics including: internal fixation products, upper and lower extremity plating and total joint reconstruction implants, soft tissue fixation and augmentation for sports medicine procedures, spinal implants for trauma, degenerative disc disease and deformity indications, and osteo-biologics, regenerative and connective tissues, which include human allografts, substitute bone materials, tendons, and regenerative tissues. Its portfolio of Orthopedic Implants and Biologics provide products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers including hospitals, medical facilities, and sub-distributors.
12GF Score
Get the complete analysis for FZMD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FZMD has been successfully added to your 
